September 28, 2011
Kowa Co., Ltd. and NanoCarrier Co., Ltd. announced on September 26 that they have signed a licensing and codevelopment agreement for NC-6300 (epirubicin micelle), an anticancer drug being developed by NanoCarrier. The agreement grants Kowa exclusive worldwide marketing and manufacturing...read more